clinical trial · NCT05736107
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Caliway Biopharmaceuticals Co., Ltd.·phase2·completed·n = 107
Subcutaneous FatCBL-514 Injection0.9% Sodium Chloride
brief summary
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing subcutaneous fat.
started
May 30, 2023
primary completion
May 20, 2024
completion
May 20, 2024
last updated
Jul 22, 2024
detailed description
A total of approximately 110 adult participants with moderate or severe abdominal fat as assessed by the Investigator via live evaluation using the Clinician-Reported Abdominal Fat Rating Scale (CR-AFRS) at Screening will be enrolled. Each participant will receive up to 4 treatments of allocated CBL-514 (2 mg/cm²) or placebo administered subcutaneously to the abdomen, once every 3 weeks.
official title
A Randomized, Placebo-Controlled, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol